Study to Compare the Pharmacokinetics, Safety and Tolerability of the Pediatric and Adult Branaplam Formulation in Healthy Adults and the Effect of Food on the Latter.
- Conditions
- Healthy Volunteers
- Interventions
- Drug: LMI070
- Registration Number
- NCT05330286
- Lead Sponsor
- Novartis Pharmaceuticals
- Brief Summary
This is a Phase 1 study designed to assess the relative bioavailability (BA), safety and tolerability and PK of the pediatric and adult formulations of branaplam.
- Detailed Description
This study is to compare the pharmacokinetics, safety and tolerability of the pediatric and adult branaplam formulation in healthy adults. The study will also clarify if dosing with food can affect the PK of the adult formulation in order to guide recommendations on dosing relative to meals in subsequent studies. It is two-part, two-period, cross-over study in healthy participants which means that participants will receive both doses and take the treatment with and without food. The total study duration for each participant is expected to be up to approximately 88 days, including the Screening period and safety FU call.
Participants will be required to be stay at the site overnight for 6 days during each period to receive dose and have multiple blood draws.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 9
-
Healthy male and non-childbearing potential female participants, 18 to 60 years of age inclusive, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening and baseline 1 (laboratory parameters are listed in Table 8-4.
-
Participants must weigh at least 50 kg at screening to participate in the study, and must have a body mass index within the range of 18.0 to 30.0 kg/m2 as measured at screening. Body mass index = Body weight (kg) / [Height (m)]2.
-
At screening and baseline vital signs (systolic blood pressure, diastolic blood pressure and pulse rate) will be assessed in the supine position and again in the standing position (after at least 3 minutes in each position). Oral body temperature will also be taken with the other supine vital sign assessments. Supine vital signs must be within the following ranges at screening and baseline 1:
- oral body temperature 35.0-37.5 °C (inclusive)
- systolic blood pressure, 90-139 mmHg (inclusive)
- diastolic blood pressure, 50-89 mmHg (inclusive)
- pulse rate, 40-90 bpm (inclusive) Participants should be excluded if their standing vital signs (relative to supine) show findings which, in the opinion of the Investigator, are associated with clinical manifestation of postural hypotension (i.e. absence of any other cause). An Investigator should carefully consider enrolling participants with either a > 20 mmHg decrease in systolic blood pressure or a > 10 mmHg decrease in diastolic blood pressure accompanied by a > 20 bpm increase in pulse rate.
-
Participants who have received any investigational medicinal product in a clinical research study within the 90 days or 5 half-lives, whichever is longer, prior to Period 1 Day 1.
-
Participants who have previously been administered investigational medicinal product in this study. Participants who have taken part in Part 1 are not permitted to take part in Part 2.
-
Significant illness, which has not resolved within two (2) weeks prior to initial dosing.
-
Men planning to father children in the near future (next 6 months).
-
Male participant who reports to have a pregnant or nursing (lactating) partner.
-
Sexually active males unwilling to adhere to the contraception requirements of the study as detailed below:
- A condom is required for all sexually active male participants to prevent them from fathering a child AND to prevent delivery of the investigational drug via seminal fluid to their partner.
- Males with partners of childbearing potential must use a condom during intercourse while taking investigational drug and for 118 days after stopping investigational drug (duration to cover one spermatogenesis cycle plus 5 half-lives).
- Additionally, male participants with female partners of childbearing potential should also use another highly effective method of contraception. Highly effective contraception methods include:
Partner's bilateral tubal occlusion Male participant sterilization (vasectomy; at least 6 months prior to screening).
Partner's use of oral (estrogen and progesterone; or progesterone only that inhibits ovulation), injected, or implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine system, or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example hormone vaginal ring or transdermal hormone contraception. In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months.
-
Total abstinence (when this is in line with the preferred and usual lifestyle of the participant). Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
-
Males with partners of non-childbearing potential must use a condom during intercourse while taking investigational drug and for 28 days after stopping investigational drug (duration to cover 5 half lives).
-
In addition, male participants should not donate sperm for 118 days after stopping investigational drug.
- Women of childbearing potential who report to be pregnant or nursing (lactating). Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant. Women are considered not of child-bearing potential if they are post-menopausal or have had surgical bilateral salpingectomy or bilateral oophorectomy (with or without hysterectomy) or total hysterectomy at least six weeks before screening. Women are considered post menopausal if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) and serum follicle stimulating hormone concentration of ≥40 IU/L. Follicle stimulating hormone and luteinizing hormone testing is required of any female participant, regardless of reported reproductive/menopausal status at screening. Refer to Section 8.4.3 Pregnancy and Assessments of Fertility.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Adult Formulation LMI070 Part 1 - healthy participants receiving adult formulation Adult formulation fasted state LMI070 Part 2- healthy participants receiving adult formulation in fasted conditions Adult formulation Fed state LMI070 Part 2- Part 2- healthy participants receiving adult formulation in fed conditions Pediatric Formulation LMI070 Part 1 - healthy participants receiving pediatric formulation
- Primary Outcome Measures
Name Time Method Part 1: Plasma Cmax Day 1, 2, 3, 4, 5, 8, 11 and 15 Assess relative bioavailability of adult vs pediatric formulation of branaplam under fasting conditions
Part 2: Plasma AUClast Day1, 2, 3, 4, 5, 8, 11 and 15 in each period Investigate food effect on the pharmacokinetics of the adult formulation of branaplam
Part 1: Plasma AUClast Day 1, 2, 3, 4, 5, 8, 11 and 15 in each period Assess relative bioavailability of adult vs pediatric formulation of branaplam under fasting conditions
Part 1: Plasma AUCinf Day 1, 2, 3, 4, 5, 8, 11 and 15 in each period Assess relative bioavailability of adult vs pediatric formulation of branaplam under fasting conditions
Part 2:Plasma Cmax Day 1, 2, 3, 4, 5, 8, 11 and 15 in each period Investigate food effect on the pharmacokinetics of the adult formulation of branaplam
Part 2: Plasma AUCinf Day 1, 2, 3, 4, 5, 8, 11 and 15 in each period Investigate food effect on the pharmacokinetics of the adult formulation of branaplam
- Secondary Outcome Measures
Name Time Method Parts 1 & 2: Plasma AUClast Day 1, 2, 3, 4, 5, 8, 11 and 15 in each period Assess the Pharmacokinetic profile of branaplam and its metabolite UFB112
Parts 1 & 2: Plasma Tmax Day 1, 2, 3, 4, 5, 8, 11 and 15 in each period Assess the Pharmacokinetic profile of branaplam and its metabolite UFB112
Parts 1 & 2: T1/2 Day 1, 2, 3, 4, 5, 8, 11 and 15 in each period Assess the Pharmacokinetic profile of branaplam and its metabolite UFB112
Parts 1 & 2: Plasma Cmax Day 1, 2, 3, 4, 5, 8, 11 and 15 in each period Assess the Pharmacokinetic profile of branaplam and its metabolite UFB112
Parts 1 & 2: Plasma Vz/F Day 1, 2, 3, 4, 5, 8, 11 and 15 in each period Assess the Pharmacokinetic profile of branaplam and its metabolite UFB112
Parts 1 &2: Plasma AUCinf Day 1, 2, 3, 4, 5, 8, 11 and 15 in each period Assess the Pharmacokinetic profile of branaplam and its metabolite UFB112
Parts 1 & 2: Plasma CL/F Day 1, 2, 3, 4, 5, 8, 11 and 15 in each period Assess the Pharmacokinetic profile of branaplam and its metabolite UFB112
Number of Adverse events and Serious adverse events Day 1 up to 30 days after last drug administration Any clinically significant events from other safety assessments will be recorded as adverse events as evaluated by investigator.
Trial Locations
- Locations (1)
Novartis Investigative Site
🇬🇧Mere Way, Nottingham, United Kingdom